Moderna's updated RSV vaccine disappoints with only 50% efficacy
Moderna reported that its vaccine was 50% effective at preventing lower respiratory disease following RSV infection, falling short of numbers reported by GSK and Pfizer heading into the fall, when...
View ArticleTaysha’s $75M offering; Augustine raises €17M
Plus, news about Agile Therapeutics, Insud, Werewolf Therapeutics and Allakos: Taysha Gene Therapies sells $75M in shares: The biotech is issuing more than 14 million shares of common stock for $2.25...
View ArticleFDA publishes long-awaited guidance on clinical trial diversity
As the White House kicked off a public forum on clinical trials on Wednesday, the FDA simultaneously published a delayed draft guidance on ensuring clinical trials become diverse. The draft guidance...
View ArticleNovo Nordisk takes $816M impairment loss after Phase 3 fail in chronic kidney...
Novo Nordisk said Wednesday morning a small molecule that it recently bought for up to $1.3 billion has failed a Phase 3 trial in chronic kidney disease. The Danish drugmaker said it will take an...
View ArticleClik here to view.
Savara’s rare lung disease treatment passes Phase 3
Savara reported that its daily treatment for a rare lung disease met the primary endpoint in a key late-stage study. The company is developing molgramostim for autoimmune pulmonary alveolar proteinosis...
View ArticleEMA calls for member states to lend a hand to ease GLP-1 supply bottlenecks
The European Medicines Agency is calling for both pharma companies and its member states to address the supply pressures on GLP-1 weight loss and diabetes drugs. The ongoing shortage for GLP-1 drugs is...
View ArticleHHS reveals 64 drugs up for Medicare inflation rebates next quarter
More drugs than ever will be subject to Medicare inflation rebates under the Inflation Reduction Act next quarter. On Wednesday, the Department of Health and Human Services revealed the 64 drugs that...
View ArticleClik here to view.
Scientists unveil new way to make large changes to genes, and no CRISPR is...
Scientists led by Patrick Hsu at the Arc Institute in Palo Alto have unveiled a new form of gene editing that can add, remove or flip large stretches of DNA — all without the help of CRISPR. CRISPR...
View ArticleClik here to view.
Optum Rx may enter biosimilar market to match competitors CVS, Express Scripts
Top PBM Optum Rx may be moving into the biosimilar business, joining its competitors CVS and Express Scripts, according to a US trademark application for a business called Nuvaila. The application to...
View ArticleClik here to view.
Updated: CDC expands RSV vaccine recommendations, namely for adults 75 and older
The CDC advisory panel that helps set US vaccine policy said the use of RSV shots should be expanded to more adults, recommending the shot for all people 75 and older and for those aged 60 to 74 at...
View ArticleFDA approves new COPD drug from Verona Pharma
The FDA approved Verona Pharma’s drug for chronic obstructive pulmonary disease, or COPD, the first maintenance treatment with a new mechanism for the ailment in over two decades, according to the...
View ArticleClik here to view.
Digital health funding flattens out, PitchBook report shows
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Despite a number of high-profile late-stage megarounds, overall funding for startups seems to have...
View ArticleFDA rejects Daiichi Sankyo's HER3 ADC, a blow to quick approval plans for...
The FDA has given a thumbs-down to Daiichi Sankyo’s HER3 antibody-drug conjugate patritumab deruxtecan. The Wednesday rejection deals a blow to the Japanese pharma’s plans for a near-term expansion of...
View ArticleAbbVie and Genmab score accelerated follicular lymphoma nod for Epkinly
AbbVie and Genmab are celebrating their second accelerated approval for Epkinly, this time in follicular lymphoma. The bispecific antibody, also known as epcoritamab, was approved on Wednesday for...
View ArticleEuroAPI overhaul comes into focus with plans to cut 550 staffers and divest...
Sanofi spin-off EuroAPI provided further details on its restructuring plan, with the company cutting 550 staffers and divesting two facilities — one in Brindisi, Italy, and the other in Haverhill, UK....
View ArticleClik here to view.
Maze spins its ALS antisense program into a secretive new company
Maze Therapeutics is putting one of its neuroscience programs into a new stealth company, months after having its partnership deal with Sanofi blocked by the FTC. The biotech’s plans were quietly...
View ArticleLongevity investors look to add $200M to the table with new growth fund
Bold Capital Partners, a life sciences and deep tech investor, is raising a new fund to support biotechs and diagnostics makers focused on “healthy human life extension.” The so-called BOLD Longevity...
View ArticleMIT scientists launch spatial biology startup to test hundreds of cell...
Therapies made from a patient’s own immune cells have spurred medical miracles for many people with advanced blood cancers, but getting those CAR-T cell therapies to work more broadly in solid tumors...
View ArticleOne Medical CEO-turned-VC wants startups that are 'disruptive from within the...
Amir Dan Rubin has had the success many healthcare executives dream about. The former CEO of One Medical grew the primary care chain to hundreds of locations and sold it last year to Amazon for $3.9...
View ArticleQ&A: Vertex’s pain research chief on moving beyond opioids, AI and how pharma...
SAN DIEGO — For savvy dealmaking, Vertex’s 2001 acquisition of Aurora Biosciences is near the top of the list. Vertex bought the San Diego biotech for $592 million in stock. The site eventually...
View Article